Strategies to enhance the anticancer potential of TNF.

Although tumor necrosis factor (TNF) antitumor activity is evident in several preclinical models and in non-comparative clinical trials, no evidence exists that TNF-based treatments increase patient survival. Furthermore, due to systemic toxicity, TNF can only be administered via sophisticated drug-delivery systems in patients with solid tumors confined to one extremity or organ. The impossibility to administer TNF systemically does not allow to test the effectiveness of this cytokine in other clinical settings for the treatment of a broader spectrum of tumor types. Dissecting the cascade of molecular events underlying tumor sensitivity to TNF researchers will allow to further exploit the anticancer potential of this molecule. The rational for the development of strategies aimed at sensitizing malignant cells to TNF is to modulate tumor-specific molecular derangements in order to maximize the selectivity of TNF cytotoxicity towards cancer. This would enhance the anticancer activity of current TNF-based locoregional regimens and would pave the way to the systemic administration of this cytokine and thus to a much wider clinical experimentation of TNF in the oncology field.

[1]  S. Tsao,et al.  Id-1 activation of PI3K/Akt/NFkappaB signaling pathway and its significance in promoting survival of esophageal cancer cells. , 2007, Carcinogenesis.

[2]  S. Shankar,et al.  Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. , 2007, Frontiers in bioscience : a journal and virtual library.

[3]  Steven J. Tucker,et al.  Elevated NF-κB responses and FLIP levels in leukemic but not normal lymphocytes: reduction by salicylate allows TNF-induced apoptosis , 2007, Proceedings of the National Academy of Sciences.

[4]  R. Weichselbaum,et al.  Local gene delivery of tumor necrosis factor alpha can impact primary tumor growth and metastases through a host-mediated response , 2007, Clinical & Experimental Metastasis.

[5]  D. Nowis,et al.  TNF potentiates anticancer activity of bortezomib (Velcade®) through reduced expression of proteasome subunits and dysregulation of unfolded protein response , 2007, International journal of cancer.

[6]  P. Brouckaert,et al.  Survival of TNF toxicity: dependence on caspases and NO. , 2007, Archives of biochemistry and biophysics.

[7]  Yiwei Li,et al.  Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy. , 2007, Mini reviews in medicinal chemistry.

[8]  R. Suzuki,et al.  Current status and future of target-based therapeutics. , 2007, Current cancer drug targets.

[9]  Simone Mocellin,et al.  Nitric oxide, a double edged sword in cancer biology: Searching for therapeutic opportunities , 2007, Medicinal research reviews.

[10]  R. Johnstone,et al.  Histone deacetylase inhibitors in cancer therapy , 2007, Expert opinion on investigational drugs.

[11]  Wenshu Chen,et al.  Sensitization of TNF-induced cytotoxicity in lung cancer cells by concurrent suppression of the NF-kappaB and Akt pathways. , 2007, Biochemical and biophysical research communications.

[12]  B. Aggarwal,et al.  Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. , 2007, Blood.

[13]  C. Libert,et al.  The use of tissue inhibitors of matrix metalloproteinases to increase the efficacy of a tumor necrosis factor/interferonγ antitumor therapy , 2007, Cancer Gene Therapy.

[14]  C. Waes.  Nuclear Factor-κB in Development, Prevention, and Therapy of Cancer , 2007 .

[15]  S. Mocellin,et al.  Towards the development of tumor necrosis factor (TNF) sensitizers: making TNF work against cancer. , 2007, Current pharmaceutical design.

[16]  O. Sezer,et al.  Proteasome as an emerging therapeutic target in cancer. , 2007, Current pharmaceutical design.

[17]  S. Ramalingam,et al.  Recent advances in targeted therapy for non-small cell lung cancer , 2007, Expert opinion on therapeutic targets.

[18]  Di Chen,et al.  The proteasome as a potential target for novel anticancer drugs and chemosensitizers. , 2006, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[19]  Jeffrey E. Lee,et al.  Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  C. Trautwein,et al.  Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. , 2006, Cancer research.

[21]  G. Shapiro,et al.  Cyclin-dependent kinase pathways as targets for cancer treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. Eggermont,et al.  TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. , 2006, The oncologist.

[23]  A. Brandes,et al.  Adult soft tissue sarcomas: conventional therapies and molecularly targeted approaches. , 2006, Cancer treatment reviews.

[24]  A. Heerschap,et al.  Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas , 2006, Investigational New Drugs.

[25]  A. Corti,et al.  Synergistic Antitumor Activity of Cisplatin, Paclitaxel, and Gemcitabine with Tumor Vasculature-Targeted Tumor Necrosis Factor-α , 2006, Clinical Cancer Research.

[26]  N. Senzer,et al.  TNFerade, an Adenovector Carrying the Transgene for Human Tumor Necrosis Factor α, for Patients With Advanced Solid Tumors: Surgical Experience and Long-Term Follow-Up , 2005, Annals of Surgical Oncology.

[27]  Li Zhao,et al.  Anticancer effect and apoptosis induction of gambogic acid in human gastric cancer line BGC-823. , 2005, World journal of gastroenterology.

[28]  R. Schiff,et al.  Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  E. Perez,et al.  Molecularly targeted therapies for breast cancer. , 2005, Cancer control : journal of the Moffitt Cancer Center.

[30]  J. Hoek,et al.  Elevated PTEN Levels Account for the Increased Sensitivity of Ethanol-exposed Cells to Tumor Necrosis Factor-induced Cytotoxicity* , 2005, Journal of Biological Chemistry.

[31]  Carlo Riccardo Rossi,et al.  Tumor necrosis factor, cancer and anticancer therapy. , 2005, Cytokine & growth factor reviews.

[32]  P. Johnston,et al.  Molecular mechanisms of drug resistance , 2005, The Journal of pathology.

[33]  B. Liu,et al.  A Novel Human Phosphatidylethanolamine-binding Protein Resists Tumor Necrosis Factor α-induced Apoptosis by Inhibiting Mitogen-activated Protein Kinase Pathway Activation and Phosphatidylethanolamine Externalization* , 2004, Journal of Biological Chemistry.

[34]  S. Mocellin,et al.  Induction of Endothelial Nitric Oxide Synthase Expression by Melanoma Sensitizes Endothelial Cells to Tumor Necrosis Factor-Driven Cytotoxicity , 2004, Clinical Cancer Research.

[35]  R. Weichselbaum,et al.  A Phase I Trial of TNFerade Biologic in Patients with Soft Tissue Sarcoma in the Extremities , 2004, Clinical Cancer Research.

[36]  H. Hondermarck,et al.  Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1). , 2004, Experimental cell research.

[37]  Yan Tang,et al.  Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signaling. , 2004, International journal of oncology.

[38]  M. Blagosklonny,et al.  Flavopiridol Induces p53 via Initial Inhibition of Mdm2 and p21 and, Independently of p53, Sensitizes Apoptosis-Reluctant Cells to Tumor Necrosis Factor , 2004, Cancer Research.

[39]  T. Cotter,et al.  The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF) , 2004, British Journal of Cancer.

[40]  R. Weichselbaum,et al.  TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Samuel Arrabal,et al.  Prion Protein Prevents Human Breast Carcinoma Cell Line from Tumor Necrosis Factor α-Induced Cell Death , 2004, Cancer Research.

[42]  G. Bieler,et al.  Zoledronate Sensitizes Endothelial Cells to Tumor Necrosis Factor-induced Programmed Cell Death , 2003, Journal of Biological Chemistry.

[43]  E. Solary,et al.  Resveratrol-induced Apoptosis Is Associated with Fas Redistribution in the Rafts and the Formation of a Death-inducing Signaling Complex in Colon Cancer Cells* , 2003, Journal of Biological Chemistry.

[44]  A. Belldegrun,et al.  Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  K. Schulze-Osthoff,et al.  Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition , 2003, Oncogene.

[46]  A. Eggermont,et al.  Current uses of isolated limb perfusion in the clinic and a model system for new strategies. , 2003, The Lancet. Oncology.

[47]  Dario Neri,et al.  Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. , 2003, Cancer research.

[48]  P. Schlag,et al.  Pentoxifyllin Attenuates the Systemic Inflammatory Response Induced During Isolated Limb Perfusion With Recombinant Human Tumor Necrosis Factor-α and Melphalan , 2003, Annals of Surgical Oncology.

[49]  J. Carretero,et al.  Tumor Cytotoxicity by Endothelial Cells , 2003, The Journal of Biological Chemistry.

[50]  Shinwu Jeong,et al.  Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-alpha or TNF-related apoptosis-inducing ligand in human cancer cell lines. , 2003, Cancer research.

[51]  Dario Neri,et al.  Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[52]  P. Rochaix,et al.  Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[53]  R. Weichselbaum,et al.  Radiation-induced tumour necrosis factor-alpha expression: clinical application of transcriptional and physical targeting of gene therapy. , 2002, The Lancet. Oncology.

[54]  Y. Hannun,et al.  Inhibition of Tumor Necrosis Factor-induced Cell Death in MCF7 by a Novel Inhibitor of Neutral Sphingomyelinase* , 2002, The Journal of Biological Chemistry.

[55]  Jing Wen,et al.  Oxidative Stress-mediated Apoptosis , 2002, The Journal of Biological Chemistry.

[56]  S. Libutti,et al.  Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy , 2002, Cancer.

[57]  S. Terlikowski.  Local immunotherapy with rhTNF-alpha mutein induces strong antitumor activity without overt toxicity--a review. , 2002, Toxicology.

[58]  M. Sporn,et al.  The Novel Triterpenoid 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) Potently Enhances Apoptosis Induced by Tumor Necrosis Factor in Human Leukemia Cells* , 2002, The Journal of Biological Chemistry.

[59]  M. Tagawa,et al.  Expression of the TNF-alpha gene on mouse lung carcinoma cells suppresses spontaneous lung metastasis without affecting tumorigenicity. , 2002, Oncology reports.

[60]  S. Fulda,et al.  IFNγ sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway , 2002, Oncogene.

[61]  G. Gores,et al.  Nitric oxide inhibits apoptosis downstream of cytochrome C release by nitrosylating caspase 9. , 2002, Cancer research.

[62]  J. Knezetic,et al.  The Role of Oxygen-Derived Free Radicals and Nitric Oxide in Cytokine-Induced Antiproliferation of Pancreatic Cancer Cells , 2002, Pancreas.

[63]  P. Vandenabeele,et al.  Lithium sensitizes tumor cells in an NF-kappa B-independent way to caspase activation and apoptosis induced by tumor necrosis factor (TNF). Evidence for a role of the TNF receptor-associated death domain protein. , 2001, The Journal of biological chemistry.

[64]  P. Vandenabeele,et al.  Lithium Sensitizes Tumor Cells in an NF-κB-independent Way to Caspase Activation and Apoptosis Induced by Tumor Necrosis Factor (TNF) , 2001, The Journal of Biological Chemistry.

[65]  D. Geller,et al.  Complex regulation of human inducible nitric oxide synthase gene transcription by Stat 1 and NF-κB , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[66]  J. Carretero,et al.  Possible mechanisms for tumour cell sensitivity to TNF-alpha and potential therapeutic applications. , 2001, Current pharmaceutical biotechnology.

[67]  I. Morita,et al.  Inhibition of phosphatidylinositol-3 kinase/Akt or mitogen-activated protein kinase signaling sensitizes endothelial cells to TNF-α cytotoxicity , 2001, Cell Death and Differentiation.

[68]  M. Qiu,et al.  Elevated superoxide production by active H-ras enhances human lung WI-38VA-13 cell proliferation, migration and resistance to TNF-α , 2001, Oncogene.

[69]  E. Clementi,et al.  Activation of the Endothelial Nitric-oxide Synthase by Tumor Necrosis Factor-α , 2001, The Journal of Biological Chemistry.

[70]  E. Regalia,et al.  Triggering of antitumor activity through melanoma-specific transduction of a constitutively active tumor necrosis factor (TNF) R1 chimeric receptor in the absence of TNF-alpha. , 2001, Cancer research.

[71]  A. Eggermont,et al.  Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions , 2000, British Journal of Cancer.

[72]  L. Stark,et al.  NF–κB kinetics predetermine TNF‐α sensitivity of colorectal cancer cells , 2000, The journal of gene medicine.

[73]  S. Libutti,et al.  Tumour necrosis factor receptor I (p55) is upregulated on endothelial cells by exposure to the tumour-derived cytokine endothelial monocyte- activating polypeptide II (EMAP-II). , 2000, Cytokine.

[74]  S. Rosenberg,et al.  Principles and Practice of the Biologic Therapy of Cancer , 2000 .

[75]  E. Clementi,et al.  Nitric oxide inhibits tumor necrosis factor-alpha-induced apoptosis by reducing the generation of ceramide. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[76]  Xiangru Lu,et al.  Tumor necrosis factor-α induces apoptosis via inducible nitric oxide synthase in neonatal mouse cardiomyocytes , 2000 .

[77]  W. Hiddemann,et al.  Induction of inducible nitric oxide synthase is an essential part of tumor necrosis factor-alpha-induced apoptosis in MCF-7 and other epithelial tumor cells. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[78]  A. Eggermont,et al.  Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. , 1999, Melanoma research.

[79]  S. Libutti,et al.  Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus. , 1999, Cancer research.

[80]  G. Rosen,et al.  PG490 (Triptolide) Cooperates with Tumor Necrosis Factor-α to Induce Apoptosis in Tumor Cells* , 1999, The Journal of Biological Chemistry.

[81]  C. Giardina,et al.  NSAIDs and butyrate sensitize a human colorectal cancer cell line to TNF-alpha and Fas ligation: the role of reactive oxygen species. , 1999, Biochimica et biophysica acta.

[82]  M. Nehls,et al.  Suppression of Apoptosis by Nitric Oxide via Inhibition of Interleukin-1β–converting Enzyme (ICE)-like and Cysteine Protease Protein (CPP)-32–like Proteases , 1997, The Journal of experimental medicine.

[83]  H. Saito,et al.  Oxidative stress‐mediated apoptosis of hepatocytes exposed to acute ethanol intoxication , 1997, Hepatology.

[84]  A. Eggermont,et al.  Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  J. Kirkwood,et al.  Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma. , 1995, The cancer journal from Scientific American.

[86]  K. Takeda,et al.  Novel muteins of human tumor necrosis factor with potent antitumor activity and less lethal toxicity in mice , 1995, International journal of cancer.

[87]  W. Fiers,et al.  Lithium chloride potentiates tumor necrosis factor-mediated cytotoxicity in vitro and in vivo. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[88]  T. Okamoto,et al.  NF-kappa B signaling and carcinogenesis. , 2007, Current pharmaceutical design.

[89]  Jie Huang,et al.  Protein kinase C-epsilon protects MCF-7 cells from TNF-mediated cell death by inhibiting Bax translocation. , 2007, Apoptosis : an international journal on programmed cell death.

[90]  B. Aggarwal,et al.  Butein, a tetrahydroxychalcone, inhibits nuclear factor (NF)-kappaB and NF-kappaB-regulated gene expression through direct inhibition of IkappaBalpha kinase beta on cysteine 179 residue. , 2007, The Journal of biological chemistry.

[91]  B. Aggarwal,et al.  apoptosis through modulation of the nuclear factor-κB signaling pathway , 2007 .

[92]  M. Konopleva,et al.  A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[93]  F. Balkwill.  TNF-alpha in promotion and progression of cancer. , 2006, Cancer metastasis reviews.

[94]  D. Goodsell.  The molecular perspective: tumor necrosis factor. , 2006, The oncologist.

[95]  Curzio Rüegg,et al.  Efficiency of recombinant human TNF in human cancer therapy. , 2006, Cancer immunity.

[96]  S. Mocellin,et al.  RNA interference: ready to silence cancer? , 2005, Journal of Molecular Medicine.

[97]  P. Clézardin.  Anti-tumour activity of zoledronic acid. , 2005, Cancer treatment reviews.

[98]  V. Rangnekar,et al.  Suppression of PTEN expression by NF-kappa B prevents apoptosis. , 2004, Molecular and cellular biology.

[99]  A. Eggermont,et al.  TNF-based isolated limb perfusion: a decade of experience with antivascular therapy in the management of locally advanced extremity soft tissue sarcomas. , 2004, Cancer treatment and research.

[100]  Xianglin Shi,et al.  Suppressed NF-kappaB and sustained JNK activation contribute to the sensitization effect of parthenolide to TNF-alpha-induced apoptosis in human cancer cells. , 2004, Carcinogenesis.

[101]  P. Brouckaert,et al.  Production and characterization of receptor-specific TNF muteins. , 2004, Methods in molecular medicine.

[102]  S. Nishida,et al.  Pretreatment with PKC inhibitor triggers TNF-alpha induced apoptosis in TNF-alpha-resistant B16 melanoma BL6 cells. , 2003, Life sciences.

[103]  K. Imai,et al.  Combination of tumor necrosis factor-alpha with sulindac in human carcinoma cells in vivo. , 2003, Annals of the New York Academy of Sciences.

[104]  B. Tsang,et al.  Resistance of human ovarian cancer cells to tumor necrosis factor alpha is a consequence of nuclear factor kappaB-mediated induction of Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory protein. , 2003, Endocrinology.

[105]  J. Minna,et al.  Sulindac enhances tumor necrosis factor-alpha-mediated apoptosis of lung cancer cell lines by inhibition of nuclear factor-kappaB. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[106]  M. Merville,et al.  NF-kappaB-dependent MnSOD expression protects adenocarcinoma cells from TNF-alpha-induced apoptosis. , 2002, Oncogene.

[107]  R. Orlowski,et al.  NF-kappaB as a therapeutic target in cancer. , 2002, Trends in molecular medicine.

[108]  B. Bonavida,et al.  Nitric oxide disrupts H2O2-dependent activation of nuclear factor kappa B. Role in sensitization of human tumor cells to tumor necrosis factor-alpha -induced cytotoxicity. , 2001, The Journal of biological chemistry.

[109]  S. Novaković,et al.  New TNF-alpha analogues: a powerful but less toxic biological tool against tumours. , 1997, Cytokine.